The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

An U.S. District Court recently ruled against Zydus and Lupin, finding Astellas's patent for Myrbetriq was not invalid. Both ...

A U.S. Federal Court has reportedly ruled in favor of Astellas Pharma in a patent litigation case over generic Myrbetriq, according to a livemint.com report. The ruling blocks Lupin and Zydus Life ...

The litigation was initiated by Astellas Pharma against Zydus Lifesciences concerning the validity of the ‘780 patent’, which ...

Astellas, a Japanese pharmaceutical company, views Vietnam as a potential market due to the country's stable economic growth ...

BEIJING—A Japanese employee of Astellas Pharma Inc. who has been detained here on suspicion of espionage since March of last year was indicted in mid-August, a source close to Japan-China ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Upstream acquired its candidate from Astellas Pharma in 2021 for an upfront payment of $81.1m, with no future payments owed to the Japanese Pharma, although due to a legacy agreement between ...

is pleased to announce a collaboration agreement with Astellas Pharma, a global life sciences company. Under the agreement, Chromatin Bioscience will use its proprietary chromatinLENS platform to ...

Patients with RA who achieve LDA with certolizumab plus methotrexate had similar rates of worsening symptoms following either ...

A federal judge in Delaware ruled in favor of Astellas Pharma Inc. on Tuesday, affirming the validity of the company's patent ...

Chromatin Bioscience, a leader in the design of synthetic promoters and gene control systems, announced a collaboration agreement with Astellas Pharma, a global life sciences company. Under the ...